Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Jones Financial Companies Lllp

Jones Financial Companies Lllp boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 75.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 303 shares of the specialty pharmaceutical company’s stock after acquiring an additional 130 shares during the period. Jones Financial Companies Lllp’s holdings in Jazz Pharmaceuticals were worth $37,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Pacer Advisors Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after buying an additional 48,708 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Jazz Pharmaceuticals by 8.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after buying an additional 59,685 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 8.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after buying an additional 42,587 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Jazz Pharmaceuticals by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company’s stock valued at $58,835,000 after buying an additional 24,481 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $187.71.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 in the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $139.51 on Wednesday. The company has a 50-day simple moving average of $130.22 and a 200-day simple moving average of $121.18. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.47 billion, a PE ratio of 19.65, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.